[{"Physician_Profile_ID": "765266", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Merck Sharp & Dohme Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NJ", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000053", "Total_Amount_of_Payment_USDollars": "122.60", "Date_of_Payment": "11/11/2013", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "24486800", "Name_of_Associated_Covered_Drug_or_Biological1": "MK-3475", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "A Phase IIIII Randomized Trial of Two Doses of MK-3475 SCH 900475 versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "765266", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Merck Sharp & Dohme Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NJ", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000053", "Total_Amount_of_Payment_USDollars": "122.60", "Date_of_Payment": "11/11/2013", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "24486799", "Name_of_Associated_Covered_Drug_or_Biological1": "MK-3475", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "A Phase IIIII Randomized Trial of Two Doses of MK-3475 SCH 900475 versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "765266", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Merck Sharp & Dohme Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NJ", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000053", "Total_Amount_of_Payment_USDollars": "122.60", "Date_of_Payment": "11/11/2013", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "24486831", "Name_of_Associated_Covered_Drug_or_Biological1": "MK-3475", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "A Phase IIIII Randomized Trial of Two Doses of MK-3475 SCH 900475 versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "765266", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Merck Sharp & Dohme Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NJ", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000053", "Total_Amount_of_Payment_USDollars": "89.30", "Date_of_Payment": "11/11/2013", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "24486512", "Name_of_Associated_Covered_Drug_or_Biological1": "MK-3475", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "A Phase IIIII Randomized Trial of Two Doses of MK-3475 SCH 900475 versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "765266", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Merck Sharp & Dohme Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NJ", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000053", "Total_Amount_of_Payment_USDollars": "89.30", "Date_of_Payment": "11/11/2013", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "24486303", "Name_of_Associated_Covered_Drug_or_Biological1": "MK-3475", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "A Phase IIIII Randomized Trial of Two Doses of MK-3475 SCH 900475 versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "765266", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Merck Sharp & Dohme Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NJ", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000053", "Total_Amount_of_Payment_USDollars": "75.84", "Date_of_Payment": "11/11/2013", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "24486511", "Name_of_Associated_Covered_Drug_or_Biological1": "MK-3475", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "A Phase IIIII Randomized Trial of Two Doses of MK-3475 SCH 900475 versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "765266", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Merck Sharp & Dohme Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NJ", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000053", "Total_Amount_of_Payment_USDollars": "61.30", "Date_of_Payment": "11/11/2013", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "24486833", "Name_of_Associated_Covered_Drug_or_Biological1": "MK-3475", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "A Phase IIIII Randomized Trial of Two Doses of MK-3475 SCH 900475 versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "765266", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Merck Sharp & Dohme Corporation", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NJ", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000053", "Total_Amount_of_Payment_USDollars": "49.04", "Date_of_Payment": "11/11/2013", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "24486832", "Name_of_Associated_Covered_Drug_or_Biological1": "MK-3475", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "A Phase IIIII Randomized Trial of Two Doses of MK-3475 SCH 900475 versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer", "Research_Information_Link": "", "Context_of_Research": ""}]